"The AGBT conference has been the site of many next generation technological unveilings during the genomics era, so we're immensely proud to have our Chief Scientific Officer, Dr. Kiana Aran, present our multiomics platform as a plenary speaker on the first day of the conference," states Michael Heltzen, CEO of Cardea Bio, and continues, "Now, we're entering a new era - real-time multiomics - through the use of Cardea's BPU platform, which Dr. Aran will showcase during her presentation today. Not only does our BPU platform have the potential to change the way you think of what's required for doing DNA testing - no amplification and no lab equipment - but the potential translates to a lot of categories ranging from rapid diagnosis of infectious diseases to liquid biopsy instruments."
The applications of this technology platform go beyond diagnostics. CRISPR-chip™ can provide greater insights on the mechanism of CRISPR and can lead to safe and more effective utilization of this gene editing technology for therapeutic applications.
Cardea’s rapidly expanding IP portfolio now has 29 broad patents issued and another 32 patents pending, cementing Cardea’s market-leader position in the graphene biosensor industry, where they are bringing the BPU™ (Biosignal Processing Unit) Platform to market.
The entire abstract for Dr. Kiana Aran’s talk, can be found here:
https://www.cardeabio.com/news/agbt-abstrat-2022
